Biomarck Pharmaceuticals Gains FDA Allowance to Begin Human Trials for Inhaled Treatment for Adults with Lung Cancer

North Carolina based Biomarck Pharmaceuticals, Inc. has received FDA allowance l to begin human trials for their patented compound BIO-11006, for adults with lung cancer.  Discovered by Dr. Ken Adler at North Carolina State University working in partnership with Biomarck, inhaled Bio-11006 has demonstrated effectiveness on human cell cultures and animals in the laboratory. It demonstrated impressive results in adult tumors and childhood cancers, specifically, Rhabdomyosarcoma, Neuroblastoma and Osteosarcoma in children. BIO-11006 has shown to be safe and tolerable in over 200 adult humans that have received the drug in previous studies for lung diseases.